DRUGS & SUPPLEMENTS
1 INDICATIONS AND USAGE
Copaxone® is indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Copaxone® is indicated for the treatment of patients with relapsing-forms of multiple sclerosis (1).
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dose
Copaxone is for subcutaneous use only. Do not administer intravenously. The recommended dose is:
Copaxone 20 mg per mL and Copaxone injection 40 mg per mL are not interchangeable.
2.2 Instructions for Use
Remove one blister-packaged prefilled syringe from the refrigerated carton. Let the prefilled syringe stand at room temperature for 20 minutes to allow the solution to warm to room temperature. Visually inspect the syringe for particulate matter and discoloration prior to administration. The solution in the syringe should appear clear, colorless to slightly yellow. If particulate matter or discoloration is observed, discard the syringe.
Areas for subcutaneous self-injection include arms, abdomen, hips, and thighs. The prefilled syringe is for single use only. Discard unused portions.
3 DOSAGE FORMS AND STRENGTHS
Copaxone is contraindicated in patients with known hypersensitivity to Copaxone or mannitol.
Known hypersensitivity to Copaxone or mannitol (4)
5 WARNINGS AND PRECAUTIONS
5.1 Immediate Post-Injection Reaction
Approximately 16% of patients exposed to Copaxone injection 20 mg per mL in the four placebo-controlled trials compared to 4% of those on placebo experienced a constellation of symptoms immediately after injection that included at least two of the following: flushing, chest pain, palpitations, anxiety, dyspnea, constriction of the throat, and urticaria. In general, these symptoms have their onset several months after the initiation of treatment, although they may occur earlier, and a given patient may experience one or several episodes of these symptoms. Whether or not any of these symptoms actually represent a specific syndrome is uncertain. Typically, the symptoms were transient and self-limited and did not require treatment; however, there have been reports of patients with similar symptoms who received emergency medical care.
Whether an immunologic or nonimmunologic mechanism mediates these episodes, or whether several similar episodes seen in a given patient have identical mechanisms, is unknown.
5.2 Chest Pain
Approximately 13% of Copaxone injection 20 mg per mL patients in the four placebo-controlled studies compared to 6% of placebo patients experienced at least one episode of transient chest pain. While some of these episodes occurred in the context of the Immediate Post-Injection Reaction described above, many did not. The temporal relationship of this chest pain to an injection was not always known. The pain was usually transient, often unassociated with other symptoms, and appeared to have no clinical sequelae. Some patients experienced more than one such episode, and episodes usually began at least 1 month after the initiation of treatment. The pathogenesis of this symptom is unknown.
5.3 Lipoatrophy and Skin Necrosis
At injection sites, localized lipoatrophy and, rarely, injection site skin necrosis may occur. Lipoatrophy occurred in approximately 2% of patients exposed to Copaxone injection 20 mg per mL in the four placebo-controlled trials compared to none on placebo. Skin necrosis has only been observed in the post-marketing setting. Lipoatrophy may occur at various times after treatment onset and is thought to be permanent. There is no known therapy for lipoatrophy. To assist in possibly minimizing these events, the patient should be advised to follow proper injection technique and to rotate injection sites with each injection.
5.4 Potential Effects on Immune Response
Because Copaxone injection can modify immune response, it may interfere with immune functions. For example, treatment with Copaxone injection may interfere with the recognition of foreign antigens in a way that would undermine the body’s tumor surveillance and its defenses against infection. There is no evidence that Copaxone injection does this, but there has not been a systematic evaluation of this risk. Because Copaxone injection is an antigenic material, it is possible that its use may lead to the induction of host responses that are untoward, but systematic surveillance for these effects has not been undertaken.
Although Copaxone injection is intended to minimize the autoimmune response to myelin, there is the possibility that continued alteration of cellular immunity due to chronic treatment with Copaxone injection may result in untoward effects.
Glatiramer acetate-reactive antibodies are formed in most patients receiving Copaxone. Studies in both the rat and monkey have suggested that immune complexes are deposited in the renal glomeruli. Furthermore, in a controlled trial of 125 RRMS patients given Copaxone injection 20 mg per mL, subcutaneously every day for 2 years, serum IgG levels reached at least 3 times baseline values in 80% of patients by 3 months of initiation of treatment. By 12 months of treatment, however, 30% of patients still had IgG levels at least 3 times baseline values, and 90% had levels above baseline by 12 months. The antibodies are exclusively of the IgG subtype and predominantly of the IgG-1 subtype. No IgE type antibodies could be detected in any of the 94 sera tested; nevertheless, anaphylaxis can be associated with the administration of most any foreign substance, and therefore, this risk cannot be excluded.
6 ADVERSE REACTIONS
To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Incidence in Controlled Clinical Trials
Copaxone Injection 20 mg per mL per day
Among 563 patients treated with Copaxone injection in blinded placebo-controlled trials, approximately 5% of the subjects discontinued treatment because of an adverse reaction. The adverse reactions most commonly associated with discontinuation were: injection site reactions, dyspnea, urticaria, vasodilatation, and hypersensitivity. The most common adverse reactions were: injection site reactions, vasodilatation, rash, dyspnea, and chest pain.
Table 1 lists treatment-emergent signs and symptoms that occurred in at least 2% of patients treated with Copaxone injection 20 mg per mL in the placebo-controlled trials. These signs and symptoms were numerically more common in patients treated with Copaxone injection than in patients treated with placebo. Adverse reactions were usually mild in intensity.
Adverse reactions which occurred only in 4 to 5 more subjects in the Copaxone injection group than in the placebo group (less than 1% difference), but for which a relationship to Copaxone injection could not be excluded, were arthralgia and herpes simplex.
Laboratory analyses were performed on all patients participating in the clinical program for Copaxone injection. Clinically-significant laboratory values for hematology, chemistry, and urinalysis were similar for both Copaxone injection and placebo groups in blinded clinical trials. In controlled trials one patient discontinued treatment due to thrombocytopenia (16 x109/L), which resolved after discontinuation of treatment.
Data on adverse reactions occurring in the controlled clinical trials of Copaxone injection 20 mg per mL were analyzed to evaluate differences based on sex. No clinically-significant differences were identified. Ninety-six percent of patients in these clinical trials were Caucasian. The majority of patients treated with Copaxone injection were between the ages of 18 and 45. Consequently, data are inadequate to perform an analysis of the adverse reaction incidence related to clinically-relevant age subgroups.
Other Adverse Reactions
In the paragraphs that follow, the frequencies of less commonly reported adverse clinical reactions are presented. Because the reports include reactions observed in open and uncontrolled premarketing studies (n= 979), the role of Copaxone injection in their causation cannot be reliably determined. Furthermore, variability associated with adverse reaction reporting, the terminology used to describe adverse reactions, etc., limit the value of the quantitative frequency estimates provided. Reaction frequencies are calculated as the number of patients who used Copaxone injection and reported a reaction divided by the total number of patients exposed to Copaxone injection. All reported reactions are included except those already listed in the previous table, those too general to be informative, and those not reasonably associated with the use of the drug. Reactions are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: Frequent adverse reactions are defined as those occurring in at least 1/100 patients and infrequent adverse reactions are those occurring in 1/100 to 1/1,000 patients.
Body as a Whole:
Infrequent: Injection site hematoma, moon face, cellulitis, hernia, injection site abscess, serum sickness, suicide attempt, injection site hypertrophy, injection site melanosis, lipoma, and photosensitivity reaction.
Infrequent: Hypotension, midsystolic click, systolic murmur, atrial fibrillation, bradycardia, fourth heart sound, postural hypotension, and varicose veins.
Infrequent: Dry mouth, stomatitis, burning sensation on tongue, cholecystitis, colitis, esophageal ulcer, esophagitis, gastrointestinal carcinoma, gum hemorrhage, hepatomegaly, increased appetite, melena, mouth ulceration, pancreas disorder, pancreatitis, rectal hemorrhage, tenesmus, tongue discoloration, and duodenal ulcer.
Infrequent: Goiter, hyperthyroidism, and hypothyroidism.
Frequent: Bowel urgency, oral moniliasis, salivary gland enlargement, tooth caries, and ulcerative stomatitis.
Hemic and Lymphatic:
Infrequent: Leukopenia, anemia, cyanosis, eosinophilia, hematemesis, lymphedema, pancytopenia, and splenomegaly.
Metabolic and Nutritional:
Infrequent: Weight loss, alcohol intolerance, Cushing’s syndrome, gout, abnormal healing, and xanthoma.
Infrequent: Arthritis, muscle atrophy, bone pain, bursitis, kidney pain, muscle disorder, myopathy, osteomyelitis, tendon pain, and tenosynovitis.
Frequent: Abnormal dreams, emotional lability, and stupor.
Infrequent: Aphasia, ataxia, convulsion, circumoral paresthesia, depersonalization, hallucinations, hostility, hypokinesia, coma, concentration disorder, facial paralysis, decreased libido, manic reaction, memory impairment, myoclonus, neuralgia, paranoid reaction, paraplegia, psychotic depression, and transient stupor.
Frequent: Hyperventilation and hay fever.
Infrequent: Asthma, pneumonia, epistaxis, hypoventilation, and voice alteration.
Skin and Appendages:
Frequent: Eczema, herpes zoster, pustular rash, skin atrophy, and warts.
Infrequent: Dry skin, skin hypertrophy, dermatitis, furunculosis, psoriasis, angioedema, contact dermatitis, erythema nodosum, fungal dermatitis, maculopapular rash, pigmentation, benign skin neoplasm, skin carcinoma, skin striae, and vesiculobullous rash.
Frequent: Visual field defect.
Infrequent: Dry eyes, otitis externa, ptosis, cataract, corneal ulcer, mydriasis, optic neuritis, photophobia, and taste loss.
Frequent: Amenorrhea, hematuria, impotence, menorrhagia, suspicious papanicolaou smear, urinary frequency, and vaginal hemorrhage.
Infrequent: Vaginitis, flank pain (kidney), abortion, breast engorgement, breast enlargement, carcinoma in situ cervix, fibrocystic breast, kidney calculus, nocturia, ovarian cyst, priapism, pyelonephritis, abnormal sexual function, and urethritis.
6.2 Postmarketing Experience
The following adverse events occurring under treatment with Copaxone injection 20 mg per mL since market introduction and not mentioned above have been identified during postapproval use of Copaxone injection. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Body as a Whole: sepsis; SLE syndrome; hydrocephalus; enlarged abdomen; allergic reaction; anaphylactoid reaction
Cardiovascular System: thrombosis; peripheral vascular disease; pericardial effusion; myocardial infarct; deep thrombophlebitis; coronary occlusion; congestive heart failure; cardiomyopathy; cardiomegaly; arrhythmia; angina pectoris
Digestive System: tongue edema; stomach ulcer; hemorrhage; liver function abnormality; liver damage; hepatitis; eructation; cirrhosis of the liver; cholelithiasis
Hemic and Lymphatic System: thrombocytopenia; lymphoma-like reaction; acute leukemia
Metabolic and Nutritional Disorders: hypercholesterolemia
Musculoskeletal System: rheumatoid arthritis; generalized spasm
Nervous System: myelitis; meningitis; CNS neoplasm; cerebrovascular accident; brain edema; abnormal dreams; aphasia; convulsion; neuralgia
Respiratory System: pulmonary embolus; pleural effusion; carcinoma of lung
Special Senses: glaucoma; blindness
Urogenital System: urogenital neoplasm; urine abnormality; ovarian carcinoma; nephrosis; kidney failure; breast carcinoma; bladder carcinoma; urinary frequency
7 DRUG INTERACTIONS
Interactions between Copaxone injection and other drugs have not been fully evaluated. Results from existing clinical trials do not suggest any significant interactions of Copaxone injection with therapies commonly used in MS patients, including the concurrent use of corticosteroids for up to 28 days. Copaxone injection has not been formally evaluated in combination with interferon beta.
8 USE IN SPECIFIC POPULATIONS
Pregnancy Category B
Administration of Copaxone by subcutaneous injection to pregnant rats and rabbits resulted in no adverse effects on offspring development. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Copaxone should be used during pregnancy only if clearly needed.
In rats or rabbits receiving Copaxone by subcutaneous injection during the period of organogenesis, no adverse effects on embryo-fetal development were observed at doses up to 37.5 mg/kg/day. In rats receiving subcutaneous Copaxone at doses of up to 36 mg/kg from day 15 of pregnancy throughout lactation, no significant effects on delivery or on offspring growth and development were observed.
8.2 Labor and Delivery
The effects of Copaxone on labor and delivery in pregnant women are unknown.
8.3 Nursing Mothers
It is not known if Copaxone is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Copaxone is administered to a nursing woman.
8.4 Pediatric Use
The safety and effectiveness of Copaxone have not been established in patients under 18 years of age.
8.5 Geriatric Use
Copaxone has not been studied in elderly patients.
8.6 Use in Patients with Impaired Renal Function
The pharmacokinetics of Copaxone in patients with impaired renal function have not been determined.
Copaxone, the active ingredient of Copaxone, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of Copaxone is 5,000 – 9,000 daltons. Copaxone is identified by specific antibodies.
Chemically, Copaxone is designated L-glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt). Its structural formula is:
(Glu, Ala, Lys, Tyr) x -xCH3COOH
(C5H9NO4-C3H7NO2-C6H14N2O2-C9H11NO3) x -xC2H4O2
CAS - 147245-92-9
Copaxone is a clear, colorless to slightly yellow, sterile, nonpyrogenic solution for subcutaneous injection. Each 1 mL of Copaxone solution contains 20 mg of Copaxone and the following inactive ingredient 40 mg of mannitol. The pH of the solution is approximately 5.5 to 7.0. The biological activity of Copaxone is determined by its ability to block the induction of experimental autoimmune encephalomyelitis (EAE) in mice.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
The mechanism by which Copaxone exerts its effects in patients with MS are not fully understood. However, Copaxone is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS. This hypothesis is supported by findings of studies that have been carried out to explore the pathogenesis of experimental autoimmune encephalomyelitis, a condition induced in animals through immunization against central nervous system derived material containing myelin and often used as an experimental animal model of MS. Studies in animals and in vitro systems suggest that upon its administration, glatiramer acetate-specific suppressor T-cells are induced and activated in the periphery.
Because Copaxone can modify immune functions, concerns exist about its potential to alter naturally-occurring immune responses. There is no evidence that Copaxone does this, but this has not been systematically evaluated .
Results obtained in pharmacokinetic studies performed in humans (healthy volunteers) and animals support that a substantial fraction of the therapeutic dose delivered to patients subcutaneously is hydrolyzed locally. Larger fragments of Copaxone can be recognized by glatiramer acetate-reactive antibodies. Some fraction of the injected material, either intact or partially hydrolyzed, is presumed to enter the lymphatic circulation, enabling it to reach regional lymph nodes, and some may enter the systemic circulation intact.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
In a 2-year carcinogenicity study, mice were administered up to 60 mg/kg/day Copaxone by subcutaneous injection (up to 15 times the human therapeutic dose of 20 mg/day on a mg/m2 basis). No increase in systemic neoplasms was observed. In males receiving the 60-mg/kg/day dose, there was an increased incidence of fibrosarcomas at the injection sites. These sarcomas were associated with skin damage precipitated by repetitive injections of an irritant over a limited skin area.
In a 2-year carcinogenicity study, rats were administered up to 30 mg/kg/day Copaxone by subcutaneous injection (up to 15 times the human therapeutic dose on a mg/m2 basis). No increase in neoplasms was observed.
Copaxone was not mutagenic in in vitro (Ames test, mouse lymphoma tk) assays. Copaxone was clastogenic in two separate in vitro chromosomal aberration assays in cultured human lymphocytes but not clastogenic in an in vivo mouse bone marrow micronucleus assay.
When Copaxone was administered by subcutaneous injection prior to and during mating (males and females) and throughout gestation and lactation (females) at doses up to 36 mg/kg/day (18 times the human therapeutic dose on a mg/m2 basis) no adverse effects were observed on reproductive or developmental parameters.
14 CLINICAL STUDIES
Evidence supporting the effectiveness of Copaxone injection derives from four placebo-controlled trials which used a Copaxone injection dose of 20 mg per mL per day.
Copaxone injection 20 mg per mL per day
Study 1 was performed at a single center. Fifty patients were enrolled and randomized to receive daily doses of either Copaxone injection, 20 mg per mL subcutaneously, or placebo (glatiramer acetate injection: n=25; placebo: n=25). Patients were diagnosed with RRMS by standard criteria, and had had at least 2 exacerbations during the 2 years immediately preceding enrollment. Patients were ambulatory, as evidenced by a score of no more than 6 on the Kurtzke Disability Scale Score (DSS), a standard scale ranging from 0–Normal to 10–Death due to MS. A score of 6 is defined as one at which a patient is still ambulatory with assistance; a score of 7 means the patient must use a wheelchair.
Patients were examined every 3 months for 2 years, as well as within several days of a presumed exacerbation. To confirm an exacerbation, a blinded neurologist had to document objective neurologic signs, as well as document the existence of other criteria (e.g., the persistence of the neurological signs for at least 48 hours).
The protocol-specified primary outcome measure was the proportion of patients in each treatment group who remained exacerbation free for the 2 years of the trial, but two other important outcomes were also specified as endpoints: the frequency of attacks during the trial, and the change in the number of attacks compared with the number which occurred during the previous 2 years.
Table 2 presents the values of the three outcomes described above, as well as several protocol-specified secondary measures. These values are based on the intent-to-treat population (i.e., all patients who received at least 1 dose of treatment and who had at least 1 on-treatment assessment):
Study 2 was a multicenter trial of similar design which was performed in 11 US centers. A total of 251 patients (glatiramer acetate injection: n=125; placebo: n=126) were enrolled. The primary outcome measure was the Mean 2-Year Relapse Rate. Table 3 presents the values of this outcome for the intent-to-treat population, as well as several secondary measures:
In both studies, Copaxone injection exhibited a clear beneficial effect on relapse rate, and it is based on this evidence that Copaxone injection is considered effective.
In Study 3, 481 patients who had recently (within 90 days) experienced an isolated demyelinating event and who had lesions typical of multiple sclerosis on brain MRI were randomized to receive either Copaxone injection 20 mg per mL (n=243) or placebo (n=238). The primary outcome measure was time to development of a second exacerbation. Patients were followed for up to three years or until they reached the primary endpoint. Secondary outcomes were brain MRI measures, including number of new T2 lesions and T2 lesion volume.
Time to development of a second exacerbation was significantly delayed in patients treated with Copaxone injection compared to placebo (Hazard Ratio = 0.55; 95% confidence interval 0.40 to 0.77; Figure 1). The Kaplan-Meier estimates of the percentage of patients developing a relapse within 36 months were 42.9% in the placebo group and 24.7% in the Copaxone injection group.
Figure 1: Time to Second Exacerbation
Patients treated with Copaxone injection demonstrated fewer new T2 lesions at the last observation (rate ratio 0.41; confidence interval 0.28 to 0.59; p < 0.0001). Additionally, baseline-adjusted T2 lesion volume at the last observation was lower for patients treated with Copaxone injection (ratio of 0.89; confidence interval 0.84 to 0.94; p = 0.0001).
Study 4 was a multinational study in which MRI parameters were used both as primary and secondary endpoints. A total of 239 patients with RRMS (glatiramer acetate injection: n=119; and placebo: n=120) were randomized. Inclusion criteria were similar to those in the second study with the additional criterion that patients had to have at least one Gd-enhancing lesion on the screening MRI. The patients were treated in a double-blind manner for nine months, during which they underwent monthly MRI scanning. The primary endpoint for the double-blind phase was the total cumulative number of T1 Gd-enhancing lesions over the nine months. Table 4 summarizes the results for the primary outcome measure monitored during the trial for the intent-to-treat cohort.
Figure 2 displays the results of the primary outcome on a monthly basis.
Figure 2: Median Cumulative Number of Gd-Enhancing Lesions
16 HOW SUPPLIED/STORAGE AND HANDLING
Copaxone (glatiramer acetate injection) is a clear, colorless to slightly yellow, sterile, nonpyrogenic solution in a 1 mL single-dose glass syringe with attached 1/2 inch length, 29 gauge needle supplied as:
Store Copaxone refrigerated at 2°C to 8°C (36°F to 46°F). If needed, the patient may store Copaxone at room temperature, 15°C to 30°C (59°F to 86°F), for up to one month, but refrigeration is preferred. Avoid exposure to higher temperatures or intense light. Do not freeze Copaxone. If a Copaxone syringe freezes, it should be discarded.
17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Instruct patients that if they are pregnant or plan to become pregnant while taking Copaxone they should inform their physician.
Immediate Post-Injection Reaction
Advise patients that Copaxone may cause various symptoms after injection, including flushing, chest pain, palpitations, anxiety, dyspnea, constriction of the throat, and urticaria. These symptoms are generally transient and self-limited and do not require specific treatment. Inform patients that these symptoms may occur early or may have their onset several months after the initiation of treatment. A patient may experience one or several episodes of these symptoms.
Advise patients that they may experience transient chest pain either as part of the Immediate Post-Injection Reaction or in isolation. Inform patients that the pain should be transient. Some patients may experience more than one such episode, usually beginning at least one month after the initiation of treatment. Patients should be advised to seek medical attention if they experience chest pain of unusual duration or intensity.
Lipoatrophy and Skin Necrosis at Injection Site
Advise patients that localized lipoatrophy, and rarely, skin necrosis may occur at injection sites. Instruct patients to follow proper injection technique and to rotate injection areas and sites with each injection to minimize these risks.
Instructions for Use
Instruct patients to read the Copaxone Patient Information leaflet carefully. Copaxone 20 mg per mL and Copaxone injection 40 mg per mL are not interchangeable. Copaxone injection 20 mg per mL is administered daily. Caution patients to use aseptic technique. The first injection should be performed under the supervision of a health care professional. Instruct patients to rotate injection areas and sites with each injection. Caution patients against the reuse of needles or syringes. Instruct patients in safe disposal procedures.
Advise patients that the recommended storage condition for Copaxone is refrigeration at 36°F to 46°F (2°C to 8°C). If needed, the patient may store Copaxone at room temperature, 59°F to 86°F (15°C to 30°C), for up to one month, but refrigeration is preferred. Copaxone should not be exposed to higher temperatures or intense light. Do not freeze Copaxone.
(Glatiramer Acetate Injection) for Subcutaneous Use
Read this Patient Information before you start using Copaxone and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.
What is Copaxone?
Copaxone is prescription medicine used for the treatment of people with relapsing forms of multiple sclerosis (MS).
It is not known if Copaxone is safe and effective in children under 18 years of age.
Copaxone is supplied as a 1 mL single dose glass syringe with attached 1/2 inch length, 29 gauge needle.
Who should not use Copaxone?
What should I tell my doctor before using Copaxone? Before you use Copaxone, tell your doctor if you:
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Copaxone may affect the way other medicines work, and other medicines may affect how Copaxone works.
Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist when you get a new medicine.
How should I use Copaxone?
What are the possible side effects of Copaxone?
Copaxone may cause serious side effects, including:
The most common side effects of Copaxone include:
Tell your doctor if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Copaxone. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store Copaxone?
Keep Copaxone and all medicines out of the reach of children.
General information about the safe and effective use of Copaxone.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use Copaxone for a condition for which it was not prescribed. Do not give Copaxone to other people, even if they have the same symptoms as you have. It may harm them.
This Patient Information Leaflet summarizes the most important information about Copaxone. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about Copaxone that is written for health professionals.
For more information, go to www.glatopa.com or call Sandoz GlatopaCare® at 1-855-452-8672.
What are the ingredients in Copaxone?
Active ingredient: Copaxone
Inactive ingredients: mannitol
INSTRUCTIONS FOR USE
(Glatiramer Acetate Injection) for Subcutaneous Use
For subcutaneous injection only.
Do not inject Copaxone in your veins (intravenously).
Do not re-use your Copaxone prefilled syringes.
Do not share your Copaxone prefilled syringes with another person. You may give another person an infection or get an infection from them.
You should receive your first dose of Copaxone with a doctor or nurse present. This might be at your doctor’s office or with a visiting home health nurse who will show you how to give your own injections.
Copaxone comes in a 20 mg Prefilled Syringe with needle attached.
Instructions for Using Your Copaxone 20 mg Prefilled Syringe dose:
How do I inject Copaxone?
Step 1: Gather the supplies you will need to inject Copaxone. See Figure A.
Step 2: Remove only 1 blister pack from the Copaxone prefilled syringe carton. See Figure B.
Step 3: Look closely at your Copaxone prefilled syringe.
Step 4: Choose your injection area. See Figure C.
Avoid about 2 inches around the belly button
Back of Hips and Arms
Fleshy areas of the upper hips, always below the waist
Fleshy areas of the upper back portion of the arms
Fleshy areas of the upper back portion
About 2 inches above the knee and 2 inches below the groin
Step 5: Prepare to give your injection.
Step 6: Clean your injection site.
Step 7: Pick up the syringe with 1 hand and hold it like a pencil. Remove the needle cover with your other hand and set it aside. See Figure E.
Step 8: Pinch about a 2 inch fold of skin between your thumb and index finger. See Figure F.
Step 9: Giving your injection.
Step 10: Give your Copaxone injection.
To inject the medicine, hold the syringe steady and slowly push down the plunger. See Figure I.
Step 11: Remove the needle.
After you have injected all of the medicine, pull the needle straight out. See Figure J.
Step 12: Use a clean, dry cotton ball to gently press on the injection site for a few seconds. Do not rub the injection site or re-use the needle or syringe. See Figure K.
Step 13: Dispose of your needles and syringes.
This Patient Information and Instructions for Use has been approved by the U.S. Food and Drug Administration.
Copaxone® and GlatopaCare® are registered trademarks of Novartis AG.
Princeton, NJ 08540
20 mg Carton
(glatiramer acetate injection)
Keep refrigerated 2° to 8°C (36° to 46°F). Protect from light.
Retain in carton.
Contains 30 Single-Use PRE-FILLED Syringes
a Novartis company
Copaxone 20 mg Carton
Copaxone pharmaceutical active ingredients containing related brand and generic drugs:
Active ingredient is the part of the drug or medicine which is biologically active. This portion of the drug is responsible for the main action of the drug which is intended to cure or reduce the symptom or disease. The other portions of the drug which are inactive are called excipients; there role is to act as vehicle or binder. In contrast to active ingredient, the inactive ingredient's role is not significant in the cure or treatment of the disease. There can be one or more active ingredients in a drug.
Copaxone available forms, composition, doses:
Form of the medicine is the form in which the medicine is marketed in the market, for example, a medicine X can be in the form of capsule or the form of chewable tablet or the form of tablet. Sometimes same medicine can be available as injection form. Each medicine cannot be in all forms but can be marketed in 1, 2, or 3 forms which the pharmaceutical company decided based on various background research results.
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.
Copaxone destination | category:
Destination is defined as the organism to which the drug or medicine is targeted. For most of the drugs what we discuss, human is the drug destination.
Drug category can be defined as major classification of the drug. For example, an antihistaminic or an antipyretic or anti anginal or pain killer, anti-inflammatory or so.
Copaxone Anatomical Therapeutic Chemical codes:
A medicine is classified depending on the organ or system it acts [Anatomical], based on what result it gives on what disease, symptom [Therapeutical], based on chemical composition [Chemical]. It is called as ATC code. The code is based on Active ingredients of the medicine. A medicine can have different codes as sometimes it acts on different organs for different indications. Same way, different brands with same active ingredients and same indications can have same ATC code.
Copaxone pharmaceutical companies:
Pharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug.
Researchers are the persons who are responsible for the scientific research and is responsible for all the background clinical trials that resulted in the development of the drug.
Frequently asked QuestionsCan i drive or operate heavy machine after consuming Copaxone?
Depending on the reaction of the Copaxone after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Copaxone not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.Is Copaxone addictive or habit forming?
Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
ReviewsDrugs.com conducted a study on Copaxone, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Copaxone consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.
The information was verified by Dr. Arunabha Ray, MD Pharmacology